{"id":"levofloxacin-amoxicillin-clavulanate","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Levofloxacin is a fluoroquinolone antibiotic that targets bacterial DNA gyrase and topoisomerase IV, essential for DNA replication and transcription. Amoxicillin/clavulanate is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by targeting penicillin-binding proteins.","oneSentence":"Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, while amoxicillin/clavulanate inhibits bacterial cell wall synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:26.013Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Community-acquired pneumonia"},{"name":"Skin and skin structure infections"}]},"trialDetails":[{"nctId":"NCT06494072","phase":"PHASE4","title":"Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2024-08-22","conditions":"Community Acquired Pneumonia in Children","enrollment":236},{"nctId":"NCT06537609","phase":"NA","title":"A Platform Trial for Gram Negative Bloodstream Infections","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2024-04-24","conditions":"Gram-negative Bacteremia","enrollment":2500},{"nctId":"NCT05079620","phase":"PHASE4","title":"Early Antibiotics After Aspiration in ICU Patients","status":"TERMINATED","sponsor":"UConn Health","startDate":"2021-11-30","conditions":"Aspiration, Aspiration Pneumonia","enrollment":5},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT03935828","phase":"PHASE2","title":"Effect of Topical Sinonasal Antibiotics","status":"WITHDRAWN","sponsor":"United States Naval Medical Center, San Diego","startDate":"2019-06","conditions":"Chronic Rhinosinusitis (Diagnosis), Antibiotic Side Effect","enrollment":""},{"nctId":"NCT02365623","phase":"PHASE2","title":"An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2015-02-18","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":6},{"nctId":"NCT05893147","phase":"NA","title":"BALANCE+ Vanguard Phase","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-08-26","conditions":"Gram-negative Bacteremia","enrollment":174},{"nctId":"NCT05867654","phase":"PHASE4","title":"Efficacy of Oral vs IV Antibiotics in the Treatment of Orofacial Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"University of Louisville","startDate":"2024-07-31","conditions":"Osteomyelitis of Jaw","enrollment":100},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT05393505","phase":"PHASE4","title":"Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-10-24","conditions":"Neutropenic Fever","enrollment":344},{"nctId":"NCT02567825","phase":"NA","title":"Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media","status":"COMPLETED","sponsor":"Alejandro Hoberman","startDate":"2015-11","conditions":"Acute Otitis Media","enrollment":250},{"nctId":"NCT05293977","phase":"NA","title":"Short-Term Use of Antibiotics and Adherence Level","status":"COMPLETED","sponsor":"Jordan University of Science and Technology","startDate":"2020-08-03","conditions":"Acute Infection","enrollment":589},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04584840","phase":"NA","title":"Initial Management of MRONJ Stages I and II, a Clinical Trial With Detection of Salivary Biomarkers","status":"UNKNOWN","sponsor":"Fundació d'investigació Sanitària de les Illes Balears","startDate":"2020-11-01","conditions":"Osteonecrosis of the Jaw, Bisphosphonate Induced, Osteonecrosis of the Jaw, Bisphosphonate Related","enrollment":50},{"nctId":"NCT01761214","phase":"NA","title":"Bacteriology and Inflammation in Bronchiectasis","status":"UNKNOWN","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2012-09","conditions":"Bronchiectasis","enrollment":80},{"nctId":"NCT01951768","phase":"PHASE4","title":"Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2013-09","conditions":"Diabetic Foot Ulcer","enrollment":88},{"nctId":"NCT02315547","phase":"NA","title":"Sputum Microbiota and the Association With Clinical Parameters in Steady-state, Acute Exacerbation and Convalescence of Bronchiectasis","status":"UNKNOWN","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2015-01","conditions":"Bronchiectasis","enrollment":120},{"nctId":"NCT03440060","phase":"NA","title":"Procalcitonin-guided Antibiotic Therapy During Severe Exacerbation of COPD","status":"UNKNOWN","sponsor":"University Hospital, Mahdia","startDate":"2017-10-05","conditions":"Acute Exacerbation Copd","enrollment":100},{"nctId":"NCT03003273","phase":"PHASE3","title":"Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study","status":"TERMINATED","sponsor":"All India Institute of Medical Sciences","startDate":"2017-01","conditions":"Neutropenia, Febrile, Pediatric Cancer","enrollment":142},{"nctId":"NCT03625739","phase":"","title":"Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis","status":"RECRUITING","sponsor":"Beijing Children's Hospital","startDate":"2018-07-01","conditions":"Tuberculosis","enrollment":800},{"nctId":"NCT02712502","phase":"","title":"Levofloxacin in Bacterial Rhinosinussitis","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2014-09","conditions":"Rhinosinusitis","enrollment":100},{"nctId":"NCT01584765","phase":"","title":"Rechallenge, Potential Drug Induced Liver Injury (Kaiser)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-02","conditions":"Drug-induced Liver Injury","enrollment":1},{"nctId":"NCT01434173","phase":"","title":"Risk of Acute Liver Injury in Users of Antimicrobials","status":"COMPLETED","sponsor":"Bayer","startDate":"2001-07","conditions":"Drug-Induced Liver Injury","enrollment":1299056},{"nctId":"NCT01660204","phase":"NA","title":"Community-Acquired Pneumonia - Study on the Initial Treatment With Antibiotics of Lower Respiratory Tract Infections","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2011-02","conditions":"Community-acquired Pneumonia","enrollment":2283},{"nctId":"NCT01450241","phase":"NA","title":"Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia","status":"WITHDRAWN","sponsor":"Rabin Medical Center","startDate":"2012-01","conditions":"Febrile Neutropenia","enrollment":""},{"nctId":"NCT01575899","phase":"PHASE4","title":"Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori","status":"TERMINATED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2007-12","conditions":"Helicobacter Pylori Infection","enrollment":208},{"nctId":"NCT00249210","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Levofloxacin Compared With Amoxicillin/Clavulanate Potassium in the Treatment of Adults With Rapid Onset of Severe Inflammation/Infection of the Sinuses","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1993-08","conditions":"Sinusitis, Maxillary Sinusitis","enrollment":614},{"nctId":"NCT00249197","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Levofloxacin Compared to Ticarcillin/Clavulanate Alone or Followed by Amoxicillin/Clavulanate in the Treatment of Complicated Skin Infections","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1997-01","conditions":"Skin Diseases, Bacterial","enrollment":413},{"nctId":"NCT00051753","phase":"PHASE3","title":"Levofloxacin In The Treatment Of Children With Recurrent And/or Persistent Acute Otitis Media","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2002-11","conditions":"Otitis Media","enrollment":1643},{"nctId":"NCT00042718","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of High Dose, Short-course Levofloxacin in the Treatment of Acute Bacterial Exacerbation (Worsening) of Chronic Bronchitis.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-11","conditions":"Bronchitis, Chronic Bronchitis","enrollment":659}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":238,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"levofloxacin; amoxicillin/clavulanate","genericName":"levofloxacin; amoxicillin/clavulanate","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, while amoxicillin/clavulanate inhibits bacterial cell wall synthesis. Used for Community-acquired pneumonia, Skin and skin structure infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}